The immune checkpoint PD-L1 alters choline kinase expression and metabolism in triple negative breast cancer cells

被引：0
|
作者：
Pacheco-Torres, Jesus [1 ]
Penet, Marie-France [1 ]
Wildes, Flonne [1 ]
Mironchik, Yelena [1 ]
Krishnamachary, Balaji [1 ]
Bhujwalla, Zaver M. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-2546
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2546
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy
    Wang, Zhiren
    Cordova, Leyla Estrella
    Chalasani, Pavani
    Lu, Jianqin
    MOLECULAR PHARMACEUTICS, 2022, 19 (12) : 4665 - 4674
  • [22] PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
    Khan, Muhammad
    Du, Kunpeng
    Ai, Meiling
    Wang, Baiyao
    Lin, Jie
    Ren, Anbang
    Chen, Chengcong
    Huang, Zhong
    Qiu, Wenze
    Yuan, Yawei
    Tian, Yunhong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Verteporfin inhibits surface PD-L1 expression in triple-negative breast cancer (TNBC) cells
    Khambati, Fatema
    Jaiswal, Neha
    Chellappan, Srikumar
    Soliman, Hatem
    CANCER RESEARCH, 2018, 78 (13)
  • [24] JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer
    Chen, M.
    Pockaj, B.
    Andreozzi, M.
    Barrett, M. T.
    Ocal, I. T.
    McCullough, A. E.
    Krishna, S.
    Anderson, K. S.
    CANCER RESEARCH, 2017, 77
  • [25] PD-L1 status of triple negative breast cancer in Russia
    Frank, G.
    Kuznetsova, O.
    Zavalishina, L.
    Andreeva, Y.
    Moskvina, L.
    Karaseva, V.
    Tjulandin, S.
    VIRCHOWS ARCHIV, 2020, 477 : S232 - S232
  • [26] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [27] Clinicopathological significance of PD-L1 expression in patients with triple-negative breast cancer
    Basheska, N.
    Ognenoska-Jankovska, B.
    HISTOPATHOLOGY, 2022, 81 : 26 - 27
  • [28] PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes
    Mardones, M. A.
    Grosser, D.
    Levin, M. K.
    Daoud, Y.
    Palucka, K.
    O'Shaughnessy, J.
    Osborne, C.
    CANCER RESEARCH, 2017, 77
  • [29] Cisplatin synergizes immune checkpoint blocking through RNFT1 mediated PD-L1 recycling in Triple Negative Breast Cancer
    Chu, Jiahui
    Zhang, Yifan
    Hua, Yijia
    Gong, Jue
    Mei, Jie
    Fu, Ziyi
    Yi, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [30] PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
    Yu, Yinan
    Jin, Xueying
    Zhu, Xiaoling
    Xu, Yan
    Si, Wei
    Zhao, Jianguo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345